ACVRL1 and breast carcinoma: Breast cancer patients exhibiting an ACVRL1hi TAM signature have significantly shorter survival, and ACVRL1 has been identified as an effector target for adjuvant anti-angiogenic immunotherapy in metastatic models [322].